Advertising to Drive MannKind (MNKD) Afrezza Awareness and Adoption in Q3, Jefferies Says

Jefferies analyst Shaunak Deepak reiterated a Buy rating and $9 price target on MannKind (NASDAQ: MNKD) after takeaways from the Jefferies 2015 Global Healthcare Conference.

Deepak commented, "During their presentation at the Jefferies Global Healthcare Conference, MNKD focused on the Afrezza launch and their ongoing efforts with partner Sanofi (SAN FP, Hold) to improve uptake. We look to advertising efforts in 3Q as a driver for Afrezza awareness and adoption, but we would not be overly concerned if the next few weeks of Afrezza prescription data look choppy."

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $5.54 yesterday.

You May Also Be Interested In

• MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
• Cytokinetics (CYTK) PT Raised to $118 at Mizuho
• Outdoor Holding (POWW) PT Raised to $2.75 at Roth/MKM, reiterates Top Pick